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Keely McDonald,5 Rodney Newberry,5 Thomas Graeber,1 Steve Horvath,6
Lee Goodglick,2,† and Jonathan Braun1,2
1Department of Molecular and Medical Pharmacology, 2Department of Pathology and Laboratory Medicine,
4Department of Medicine, 6Department of Human Genetics and Biostatistics, University of California Los Angeles David Geffen
School of Medicine, Los Angeles, California; 3Inﬂammatory Bowel and Immunobiology Research Institute, Cedars-Sinai
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SUMMARY
By using metaproteomics of the human colonic mucosal
surface, we found evidence for a proteomic ecology of
millimeter-scale protein networks distinguished by func-
tional specialization and cell source predominance, and their
relative abundance across colonic regions and in health vs
quiescent inﬂammatory bowel disease.
BACKGROUND & AIMS: Interactions between mucosal cell
types, environmental stressors, and intestinal microbiota
contribute to pathogenesis in inﬂammatory bowel disease
(IBD). Here, we applied metaproteomics of the mucosal–
luminal interface to study the disease-related biology of the
human colonic mucosa.
METHODS:We recruited a discovery cohort of 51 IBD and non-
IBD subjects endoscopically sampled by mucosal lavage at 6
colonic regions, and a validation cohort of 38 no-IBD subjects.
Metaproteome data sets were produced for each sample and
analyzed for association with colonic site and disease state
using a suite of bioinformatic approaches. Localization of select
proteins was determined by immunoblot analysis and immu-
nohistochemistry of human endoscopic biopsy samples.
RESULTS: Co-occurrence analysis of the discovery cohort meta-
proteome showed that proteins at the mucosal surface clustered
into modules with evidence of differential functional specializa-
tion (eg, iron regulation,microbial defense) and cellular origin (eg,
epithelial or hemopoietic). These modules, validated in an inde-
pendent cohort, were differentially associated spatially along the
gastrointestinal tract, and 7 modules were associated selectively
with non-IBD, ulcerative colitis, and/or Crohn’s disease states. In
addition, the detailed composition of certain modules was altered
in disease vs healthy states. We conﬁrmed the predicted spatial
and disease-associated localization of 28 proteins representing 4
different disease-related modules by immunoblot and immuno-
histochemistry visualization, with evidence for their distribution
as millimeter-scale microgeographic mosaic.
CONCLUSIONS: These ﬁndings suggest that the mucosal sur-
face is a microgeographic mosaic of functional networks
reﬂecting the local mucosal ecology, whose compositional
differences in disease and healthy samples may provide a
unique readout of physiologic and pathologic mucosal states.
(Cell Mol Gastroenterol Hepatol 2016;2:567–583; http://
dx.doi.org/10.1016/j.jcmgh.2016.05.003)
Keywords: Inﬂammatory Bowel Disease; Mucosal; Networks;
Ecology; Metaproteomics.
The intestinal mucosa plays diverse and critical rolesin nutrient uptake, host defense, and local and
systemic endocrinology.1–4 The functional state of the mu-
cosa in health and disease can be affected profoundly by its
interplay with environmental metabolic stressors and
luminal intestinal microbiota.4,5 Studying the mucosal–
luminal interface (MLI) and how it is changed in disease is
difﬁcult because of the many dimensions of complexity of
this ecosystem.6,7 The analytic challenge is central to the
pathogenesis of inﬂammatory bowel disease (IBD), which is
a multifactorial process involving genetic susceptibility,
environmental factors, and microbiota.8,9
Metaproteomics is an emerging technology to address this
challenge. The metaproteome of the mucosal surface is a
composite of human and microbial products, skewed for
proteins devoted to translation, energy, carbohydrate meta-
bolism, and antimicrobial defense.10–16 Focusing on the met-
aproteome recovered by lavage from the MLI of healthy
†Deceased.
Abbreviations used in this paper: ANOVA, analysis of variance; CD,
Crohn’s disease; HBD, human b-defensin; HD5, human alpha defensin
5; HNP, human neutrophil peptide; HPLC, high-performance liquid
chromatography; IBD, inﬂammatory bowel disease; IHC, immunohis-
tochemistry; MALDI, matrix-assisted laser desorption/ionization; MFN,
mucosal functional network; MLI, mucosal–luminal interface; MS/MS,
tandem mass spectrometry; NLME, nonlinear mixed-effect model;
PVCA, principal variance component analysis; TOF, time of ﬂight; UC,
ulcerative colitis; WGCNA, weighted correlation network analysis.
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human subjects,wepreviously observed that the predominant
feature is intersubject variation, with an additional signiﬁcant
intestinal segmental pattern of the surface metaproteome
distinguishing the distal and proximal colon.10 A similar
segmental difference was observed in foundational studies of
the mucosal bacterial composition.17,18 In view of emerging
concepts of intestinal ecology, this suggests that the meta-
proteome reﬂects the human contribution to the mucosal
habitat.19 With this foundation, this study applies meta-
proteomic analysis to characterize the disease-related features
of the MLI in ulcerative colitis (UC) and Crohn’s disease (CD).
Materials and Methods
Mucosal Lavage Sample Collection and Analysis
The overall study design is shown in the ﬂowchart in
Figure 1. The demographics of the study population and the
sample characteristics are summarized in Table 1. All
enrolled subjects at both Cedars Sinai Medical Center and
the University of California Los Angeles Ronald Reagan
Medical Centers were consented to participate in research
studies approved by the Institutional Review Board. CD and
UC subjects were recruited from those undergoing surveil-
lance colonoscopy; lavage samples were taken from mucosal
sites that were endoscopically normal. Non-IBD control
subjects were recruited from patients undergoing colonos-
copy for colorectal screening. For each patient, 6 colonic
regions were sampled and collected by endoscopic lavage.
All sample collections and processing followed the pre-
analytic proteomic pipeline previously detailed.10 The
demography of an independent control data set of 205
mucosal lavage samples from 38 non-IBD subjects, used as
a validation cohort for this study, was reported
previously.10
Figure 1. Flowchart of
metaproteomic analytic
pipeline.
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Protein Identiﬁcation
Protein identiﬁcation was performed by an in silico
search, followed by two strategies: immunoprecipitation
matrix-assisted laser desorption/ionization (MALDI) (when
the antibodies against the target proteins were available), or
high-performance liquid chromatography (HPLC) isolation
followed by tandem mass spectrometry (MS/MS) fragmen-
tation. An in silico search for putative protein identities was
performed using the Empirical Proteomics Ontology
Knowledge Base.20 When a speciﬁc antibody was available,
the in silico identiﬁcation was validated by immunoprecip-
itation of the original clinical isolate using an antibody
speciﬁc to the protein of interest, and magnetic beads con-
jugated with either protein A or G (Invitrogen, Carlsbad, CA).
After washing and desalting, speciﬁcally bound peptides
were extracted with formic acid and mixed with matrix for
spotting on a MALDI target. Protein identiﬁcation was per-
formed by conﬁrming the expected m/z of the original
peptide extracted by antibody, as well as examining the
immunodepleted clinical sample to see if the same peptide/
protein mass was reduced quantitatively.
In the second strategy, MALDI MS–deﬁned peptides of
interest were fractionated and isolated by HPLC. Puriﬁed
peptides smaller than 10 kilodaltons were fragmented
directly by LC-MS/MS coupled to a Nano2DLC pump
(Eksigent, Dublin, CA) and LTQ-Orbitrap (Thermo Fisher
Scientiﬁc, Waltham, MA), or by Ultraﬂex MALDI-TOF/TOF
(time of ﬂight) with LIFT technology (Bruker, Billerica,
MA). Puriﬁed peptides larger than 10 kilodaltons were
digested with trypsin in solution, or in a gel plug
after running a sodium dodecyl sulfate–polyacrylamide
gel electrophoresis, and the fragments were analyzed by
LC-MS/MS. Proteins were identiﬁed by searching
against the SwissProt database using Mascot (Matrix Sci-
ence Inc, Boston, MA), and only proteins with a P value less
than .05 were included in the results.
Immunoblotting
Ten mucosal lavage samples from each patient group
were selected randomly, including 5 from proximal and 5
from distal regions, and 50 mg protein was immunoblotted
to ensure equal loading. A Tris-glycine gel system with 0.2-
mm nitrocellulose membranes was used for proteins greater
than 5 kilodaltons, and a tricine system with 0.1-mm
Immobilon-PSQ membranes (followed by 25% glutaralde-
hyde ﬁxation) was used for smaller proteins/peptides
(Millipore, Billerica, MA; Invitrogen, Carlsbad, CA). Primary
antibodies included rabbit anti–human neutrophil peptides
(HNPs)1–3, rabbit anti-human alpha defensin 5 (HD5),
rabbit anti–human b-defensin (HBD)1, rabbit anti-HBD2,
rabbit antihepcidin (all gifts from Dr Tomas Ganz’s labora-
tory at the University of California Los Angeles). Purchased
antibodies included mouse anti-Peptidase M20 Domain
Containing 1 (PM20D1) (ab70916; Abcam, Cambridge,
United Kingdom), and rabbit anti-transferrin (ab30525;
Abcam). Secondary antibodies were horseradish perox-
idase–conjugated goat anti-rabbit or goat anti-mouse IgG
(Jackson ImmunoResearch, West Grove, PA) developed with
enhanced chemiluminescence (ECL) substrate (Pierce, IL),
or alkaline phosphatase–conjugated goat anti-rabbit IgG
antibody (Jackson ImmunoResearch) developed with BCIP
(5-bromo-4-chloro-3-indolyl-phosphate)/NBT (nitro blue
tetrazolium) substrate (MP Biomedicals, Santa Ana, CA). For
quantitation, blots were digitized and pixels were quanti-
tated by Adobe Photoshop (Adobe, San Jose, CA). Each pixel
count was normalized by dividing it with the background
pixel count.
Immunohistochemistry
To examine the cross-sectional histology of human
mucosa, microtome sections of parafﬁn tissues were ob-
tained from an independent non-IBD human cohort, and
stained by immunohistochemistry with primary antibody
and developed by VECTASTAIN Elite ABC Kit (Vector Lab,
Burlingame, CA) as previously described.21 The same an-
tibodies used in immunoblotting also were used in
immunohistochemistry (IHC), with the exception that the
antihepcidin antibody was replaced by an antiprohepcidin
antibody (gifts from Dr Tomas Ganz’s laboratory). To
examine whole-mounts of intestinal mucosa, 3 cm2 human
intestinal samples were processed as previously
described,22 and reacted with biotin-conjugated primary
antibodies using EZ-link Sulfo-NHS-Biotin (Thermo Fisher
Scientiﬁc). Detection was accomplished with horseradish
peroxidase–conjugated streptavidin antibody (Jackson Lab,
Bar Harbor, ME) and 3’-diaminobenzidine metal peroxide
substrate.
Data Analysis
All analyses were conducted using R software (available
from: www.r-project.org). The preprocessing procedures of
proteomics data have been described in detail previously.10
Here, we focused on assembling a bioinformatics pipeline
using readily available statistical tools to resolve unique
challenges in analyzing proteomic data and distill useful and
biologically relevant information.
Because of multiple sources of variance in the meta-
proteome data set, we ﬁrst used the principal variance
Table 1.Summary of Sample Collection and Clinical
Characteristics
Normal UC CD
Total subjects 17 13 21
Total mucosal lavage samples 81 75 101
Sex
Female 34 (42%) 35 (47%) 36 (36%)
Male 47 (58%) 40 (53%) 65 (65%)
Age, median ± SD, y 56 ± 13 60 ± 10 40 ± 10
Region
Cecum 14 (17%) 12 (16%) 8 (8%)
Ascending 14 (17%) 13 (17%) 16 (16%)
Transverse 14 (17%) 13 (17%) 19 (19%)
Descending 15 (19%) 11 (16%) 19 (19%)
Sigmoid 12 (15%) 13 (17%) 19 (19%)
Rectum 12 (15%) 13 (17%) 20 (19%)
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component analysis (PVCA) R package23 to evaluate the
intersubject and intrasubject variance. Sources of variance
included in our analysis were subject, collection site, colonic
region, diagnosis, sex, and age (Table 1). The PVCA in-
tegrates 2 methods: principal components analysis (which
ﬁnds low-dimensional linear combinations of data with
maximal variability) and variant component analysis (which
attributes and partitions variability into known sources via
a classic random-effects model). The signiﬁcance of the
difference from the attributed variance was evaluated with a
nonlinear mixed-effect model (NLME), and a permutation
test was used to further evaluate the biogeographic feature
by comparing two colonic sites at a time. NLME modeling
accounted for both ﬁxed effects (eg, diagnosis and biogeo-
graphic) and random effects (eg, subject), and thus was a
good ﬁt for analyzing this data set. Each NLME model was
evaluated using analysis of variance (ANOVA), and the P
values were plotted for visualization of the signiﬁcance of
the effect of interest. For the permutation test, the data set
was divided into 6 sub–data sets based on the colonic re-
gion. The mean distance was calculated between two
sub–data sets containing different colonic regions (referred
to as the actual distance). The two sub–data sets then were
permutated randomly 1000 times and the mean distance
was calculated after every permutation. If the difference
between the two regions was not signiﬁcant, the permuta-
tion should have a random effect on the mean distance.
After each permutation test, we calculated the probability
using the following formula: (the number of permutated
mean distances that are larger than the actual mean dis-
tance)/1000. If the probability was less than 0.05, the
interpretation was that the chance of observing such dif-
ference between the two colonic regions being a random
event is less than 5%.
To help distill the number of variables for further vali-
dation, weighted correlation network analysis (WGCNA)
was used to construct protein modules (deﬁned as branches
of a hierarchical cluster tree based on the topologic over-
laps).24,25 A signed, weighted adjacency protein network
was deﬁned by applying a soft threshold of 6, chosen with
the scale-free topology criterion.24 Once the network was
constructed, modules then were deﬁned by applying the
dynamic tree cut method from the package dynamicTreeCut
with a minimal module size of 10 protein members, and
similar modules were merged with a height cut of 0.4,
corresponding to a correlation of 0.6.
There is extensive literature comparing clustering pro-
cedures, including simple k-means, partitioning around
medoid, hierarchical clustering, message passing, and
model-based methods.25–27 Here, different clustering pro-
cedures (hierarchical clustering, partitioning around medoid
clustering) and dissimilarity measures (Topological Overlap
Matrix (TOM) dissimilarity, adjacency matrix, or correla-
tion) were used to produce clusterings on the same IBD data
set for comparison with those produced by WGCNA. The
degree of agreement between different cluster assignments
was measured using the Rand28 index. WGCNA-based clus-
ters were compared with hierarchical clustering resulting
from adjacency matrix-based dissimilarity (Supplementary
Table 1, top 2 tables), partitioning around medoids clus-
tering with adjacency (Supplementary Table 1, middle 2
tables), and partitioning around medoids clustering with a
correlation matrix-based dissimilarity (Supplementary
Table 1, bottom 2 tables). We found high pairwise Rand28
indices (0.796, 0.858, and 0.861, respectively). This anal-
ysis indicated that the protein modules uncovered by
WCGNA could be reproduced with any of these alternative
clustering procedures.
To test the reproducibility of the identiﬁed modules
across independent data sets, a module preservation test
was performed using two independent data sets: the IBD
data set and a normal data set published previously.10 The
two data sets were compared, and reduced to include only
common peaks shared by both data sets. Two functions, the
Z-summary test and the median rank test were imple-
mented in the WGCNA package.29 An advantage of the
Z-summary statistic is that it allows for signiﬁcance
thresholds: a Z-summary < 2 indicates no signiﬁcant mod-
ule preservation; 2 < Z-summary < 10 indicates moderate
preservation; and a Z-summary > 10 indicates strong
preservation. The median rank statistic, another network-
based module-preservation statistic, allows modules to be
ranked with respect to preservation. Statistical advantages
of the median rank statistic include computational speed
and the result is independent of module size. However,
because the median rank statistic does not make use of a
permutation test, it cannot be used to assign signiﬁcance
thresholds. Alternative statistics are available to assess the
quality and reproducibility of clusters among data sets.30–33
Our previous work outlined 7 simulation scenarios in which
we compared WGCNA’s module preservation statistics with
the hitherto best-performing alternative approach, and the
Z-summary statistic had distinct advantages when it came to
studying the preservation of network modules.29,34 Detailed
discussions of the pros and cons of these statistics were
presented recently.25,35
To summarize the proﬁles of each module, we calculated
the weighted average value (deﬁned as the left singular
vector that explains the highest amount of the underlying
variation), referred to as the eigenprotein of each module.
The Kruskal–Wallis test was used to determine whether the
eigenprotein represented intestinal segments and/or
disease-related features. To examine the signiﬁcance of
differences observed in immunoblotting, ANOVA was used
for quantiﬁed data, whereas the Fisher exact test was used
for cross-tabulation data.
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.
Results
Proﬁling the Mucosal Metaproteome
in IBD Patients
MALDI-TOF mass spectrometry was used to analyze
each lavage sample in duplicate or triplicate using a
rigorous pipeline to ensure reproducible intersample com-
parisons. A total of 599 protein/peptide features (peaks)
from 677 spectra were selected for subsequent analysis
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(Supplementary Table 2). In our previous study,10 we used a
shotgun proteomic method (MS/MS fragmentation and
high-probability matching to the nonredundant Uniprot
database (www.uniprot.org) indexed for bacteria and hu-
man proteins) to characterize the metaproteome composi-
tion of the soluble component of the mucosal lavage
compartment (the biospecimen used in the present study).
Sixty-three percent of the proteins were human proteins
and 30% were bacterial. Among the bacterial proteins, 48%
belonged to Bacteroidetes, the most abundant phylum of
human intestinal microbiota. We also observed proteins
from other bacterial phyla, including Proteobacteria, Acid-
obacteria, Firmicutes, Chlorobi, and Cyanobacteria. These
ﬁndings showed that mucosal lavage proteins represent a
mixture of host and microbial products.
An analysis of the region- and disease-related effects on
the human mucosal metaproteome is presented in Figure 2
using PVCA. The ﬁrst component (PC1) accounted for 16.6%
of the total variance in the data (Figure 2A), and the inter-
subject (individual) factor contributed the majority of the
variance (57.5%). Consistent with our previous study, the
relative contributions to the metaproteome were inter-
subject variability (57.5%), disease-related feature (21.5%),
and colonic segmental feature (15%) (Figure 2B), which
explains why we could not observe a clear separation on
the principle component plots of PC1 and PC2 (Figure 2C
and D).
To further examine these factors, we used NLME
modeling to account for individual variations, and to
calculate the signiﬁcance of the biologically relevant fea-
tures for each peak. A substantial fraction of the proteins
were detected differentially among the 6 different colonic
regions (Figure 2E and G), and 3 disease groups (Figure 2F).
At an uncorrected signiﬁcance threshold of 0.05, 191 peaks
(31.9%) were signiﬁcantly different for the biogeographic
regional feature and 146 peaks (24.4%) were signiﬁcant as
a disease-related feature. To account for multiple compari-
sons, we also used a false-discovery rate threshold of 0.1,
which resulted in 166 peaks that were signiﬁcant for re-
gions and 85 peaks that were signiﬁcant for disease
(Supplementary Table 3).
Deﬁnition and Preservation of Protein
Modules at the Mucosal Surface
To explore which proteins contributed to the segment-
or disease-related features at the mucosal surface, we
assessed the formation of protein modules, where proteins
within the same module share connectivity through similar
quantitative expression and localization features.36 We hy-
pothesized that such protein modules exist at the MLI, and
that some may show segment- or disease-related features.
We tested this hypothesis using weighted correlation
network analysis (implemented in the WGCNA R pack-
age)24,25 to construct mucosal protein modules from meta-
proteomic data, calculate eigenprotein values to quantitate
the representation of the modules among samples, and
deﬁne intramodular hub proteins.37
By using this approach, 9 distinct protein modules were
identiﬁed in the IBD data set (Figure 3A). Because module
detection does not make use of prior biological knowledge
about the protein, the biological meaning of each module
initially is unknown and hence modules initially are
assigned a color label (Table 2). To determine the statistical
robustness of these protein modules, we used 3 different
clustering and dissimilarity methods on the same IBD data
set, and compared the resulting clustering with those pro-
duced by WGCNA. We found that clusters were highly
robust across the 3 independent methodologies
(Supplementary Table 1).
Next, we tested the preservation of the modules between
independent data sets: the present IBD data set, and a
previously published normal dataset,10 an independent
metaproteomic data set of 205 mucosal lavage samples from
38 non-IBD subjects. By using the same WGCNA method,
analysis of the normal data set discovered 6 distinct protein
modules (Figure 3B). To compare protein peaks from the 2
data sets, we smoothed the spectra at 5 m/z to minimize the
isotopic effect on peak ascertainment. This yielded 346
shared peaks, shared in both data sets and selected for
module preservation analysis. The reduced common set of
shared peaks yielded the same module organization: 9
modules in the IBD data set (Figures 3C, upper color panel
IBD), and 6 modules in the normal data set (Figure 3D,
upper color panel normal ).
When the protein memberships of the modules from the
2 data sets were compared (Table 3 and Figure 3C and D,
lower color panel), 4 modules were concordant: cyan, green,
black, and brown. The membership of the largest module
detected in the control data set (yellow) was divided into 4
submodules in the IBD data set (the pink, yellow, red, and
blue modules). The diversiﬁcation of the yellow module
indicates that the detailed protein composition of the
module changes in disease compared with normal condi-
tions, which is reﬂected in altered module formation.
To evaluate quantitatively the degree of module
preservation across independent data sets, we used the Z-
summary (Figure 4E and F) and median rank test (Figure 4G
and H) statistics.29 As expected, all modules except one from
the normal data set were highly preserved in the IBD data
set; only the small purple module was absent in the IBD
data set. Conversely, except for the orange and yellow
Figure 2. (See previous page). Features of IBD mucosal metaproteome. (A) Principal components analysis of the meta-
proteome. (C) Samples colored by colonic regions plotted against PC1 and PC2. C, cecum; A, ascending; T, transverse;
D, descending; S, sigmoid; R, rectum. (D) Samples colored by diseases plotted against PC1 and PC2. N, non-IBD; U,
ulcerative colitis; C, Crohn’s disease. (B) Variance components analysis of the principal component 1. (E) Frequency plot of
region-related P value for each protein feature from NMLE analysis. (F) Frequency plot of disease-related P value for each
protein feature from NMLE analysis. (G) P values between colon regions from the permutation test analysis. Only signiﬁcant
P values (<.05) are shown.
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modules in the IBD data set, all other IBD modules also were
well preserved in the normal data set. Thus, it appeared that
there were 4 core modules (cyan, green, black, and brown)
shared in both normal and IBD data sets.
Association of Protein Modules With
Intestinal Segments and IBD Diagnosis
To test if any IBD modules showed colonic segment- or
disease-related features, we compared the eigenprotein of
each module in different colon regions or diseases using the
Kruskal–Wallis test. Three modules showed a signiﬁcant
segment-related feature (yellow, blue, and red modules),
which each were more abundant in the distal colon. Six
modules were signiﬁcantly disease-related: the green mod-
ule was increased in CD; the expression of the brown and
black modules was reduced in both UC and CD, the yellow
module (distal colon-related) was increased in both UC and
CD, and the blue and red modules (distal colon-related)
were increased in UC (Table 2).
Characterizing Individual Protein Modules
To characterize individual modules, we used several
strategies to obtain protein identities of module-associated
peaks. The identiﬁed protein peaks are listed in Table 4,
representing 6 of the 9 IBD modules. We then selected 4
modules for detailed analysis, based on the following
criteria: biologically relevant annotation, availability of
detection antibodies, and association with disease-
associated modules (Table 2; Figures 4, 5, 6, and 7).
We ﬁrst plotted the yellow module eigenprotein vs dis-
ease status (Figure 4A). The eigenprotein had a signiﬁcantly
higher value in both UC and CD samples compared with
normal, indicating that the proteins of this module are more
abundant in diseased individuals. The yellow module had
both segmental and disease-related features. Therefore, we
separated the samples according to these locations, and
visualized the samples from cecum and sigmoid separately
(Figure 4B). An in silico search and immunoprecipitation
followed by MALDI MS established their identity as a-
defensins, including HNP 1 (3442.69 m/z), HNP2 (3771.75
m/z), and HNP3 (3486.84 m/z). When we visualized each
protein level using beanplots, they all shared a similar
expression pattern, with increased levels in both UC and CD
patients (Figure 4B). Immunoblotting showed that 8 of 10
CD samples and 6 of 10 UC samples were positive
(Figure 4C, top panel). When the immunoblot data were
quantitated by digitization and normalization, a signiﬁcant
difference between disease and normal samples was
observed (Figure 4C, lower panel), formally established by
ANOVA of disease and normal groups (P ¼ .02). As expected,
tissue expression of HNP1-3 by IHC staining established that
these proteins were associated with sites of tissue neutro-
phil inﬁltration (Figure 4D), and such sites were strongly
positive in all UC and CD biopsy samples that were
evaluated.
The blue module was the largest protein network, con-
taining 180 proteins. Its eigenprotein was signiﬁcantly
lower in CD subjects compared with both normal and UC
subjects (Figure 5A). We were able to identify 2 peaks in
Figure 3. (See previous page). Deﬁnition and preservation of protein modules at the mucosal surface. (A) Dendrogram of
9 protein modules for 599 protein features from the IBD data set. (B) Dendrogram of 7 protein modules for 438 protein features
from the normal data set. Each module was designated by a different color. (C) Preservation of normal modules in the IBD
metaproteomic data set. Upper color panel: dendrogram of overlapped peaks generated by WGCNA in the reduced IBD data
set. Lower color panel: the corresponding module color of the same peak in the reduced normal data set. (D) Preservation of
IBD modules in the normal metaproteomic data set. Upper color panel: dendrogram of overlapped peaks generated by the
WGCNA in the reduced normal data set. Lower color panel: the corresponding module color of the same peak in the reduced
IBD data set. (E) Preservation Z-summary test of IBD modules. (F) Preservation Z-summary test of normal modules. Less than
0, no preservation; 0–2, weak preservation; 2–10, moderate preservation; and more than 10, high preservation. (G) Preser-
vation median rank test of IBD modules. (H) Preservation median rank test of normal modules. Each module was ranked based
on its degree of preservation.





P valuea Disease association
Region-related
P valuea Regional association
Cyan 41 ENPP7 .46 N/A .89 N/A
Green 32 HBD .038 Increased in CD only .98 N/A
Orange 15 N/A .39 N/A .64 N/A
Black 31 N/A <.001 Reduced in both UC and CD .94 N/A
Brown 17 HD5 <.001 .099 N/A
Pink 76 Elastase .45 N/A .72 N/A
Yellow 34 HNP .01 Increased in both UC and CD <.001 Increased in distal colon
Red 111 N/A .03 Increased in UC only .003
Blue 226 Hepcidin <.001 .005
aP values were generated using the Kruskal–Wallis test. P < .05 is considered statistically signiﬁcant.
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this module using HPLC followed by LC-MS/MS. The peak at
2781.92 m/z was hepcidin and the peak at 2721.85 m/z
was a transferrin protein fragment. When we plotted these
2 proteins, we noticed that both were increased slightly in
the cecal samples from UC patients (Figure 5B). Immuno-
blotting of both proteins also showed higher expression in
UC samples (Figure 5C), but only transferrin reached sig-
niﬁcance by the Fisher exact test (P ¼ .01). To test the
cellular origins of the intestinal hepcidin and transferrin, we
performed IHC staining on biopsy tissues from human co-
lons. The major cellular source of hepcidin was epithelial
cells, because these cells expressed the presecretory pro-
hepcidin molecule in a perinuclear vesicular site
(Figure 5D). On rare occasions, we also observed some
sporadic lamina propria hepcidin-positive cells, which might
represent macrophages or monocytes that are known to
express hepcidin.38 Normal or CD tissues uniformly showed
weak or no signal for prohepcidin, but all UC samples had
moderate to high signal levels. For transferrin, a gradient
expression pattern was observed in 4 of the UC tissues,
which showed higher signals toward the bottom of the
crypts but lower signals toward the mucosal surface.
Transferrin was localized to the lamina propria interstitium
and diffuse intracellular uptake, apparently reﬂecting a
vascular leak of plasma transferrin and local cellular uptake
(Figure 5D, box). In this small sampling, normal and CD
tissues had minimal signal for transferrin, with the excep-
tion of 1 CD sample with very high transferrin localization.
The green module eigenprotein was signiﬁcantly lower
in CD compared with both normal and UC (Figure 6A),
which indicates that these proteins are greatly diminished in
CD patients. Two abundant peaks of the green module
(3992.28 m/z and 4317.93 m/z) were identiﬁed success-
fully through a combination of in silico search and IP-MALDI
as HBD1 and HBD2. When we plotted the intensity of each
protein on a beanplot, both were increased in CD patients,
but decreased in UC patients (Figure 6B). We conﬁrmed this
trend by immunoblotting (Figure 6C), and ANOVA of the
digitized immunoblot data established a signiﬁcant increase
of HBD1 and HBD2 (P ¼ .04). To explore the cellular origins
of the intestinal HBD1 and HBD2, we performed IHC on
biopsy samples from human colon. We tested 5 biopsy
specimens in each group, and found both HBD1 and HBD2
were expressed exclusively in colonic epithelial cells
(Figure 6D, top and middle panels). For HBD1, 3 of 5 normal
and all UC tissues showed weak staining, but all 5 CD tissues
were strongly positive. For HBD2, all CD samples were very
strongly stained; in contrast, UC samples had weak or no
signal, and normal tissues uniformly showed a moderate
signal. Another peptide also identiﬁed within the green
module was a fragment of PM20D1, which shared the same
expression pattern as HBD1 and HBD2, with the highest
expression in CD patients (Figure 6B and C). By using both
immunoblotting and IHC, we also found high levels of
PM20D1 in CD only (Figure 6D, bottom panel).
The brown module was notable for the presence of a-
defensin 5 (HD5) (Table 4). HD5 is secreted speciﬁcally by
Paneth cells that classically reside in the small intestine.39,40
Its presence in lavage samples may have reﬂected distal
luminal migration to the colon from the small intestine.
However, IHC staining showed that speciﬁc HD5-positive
cells were readily detectable in the characteristic crypt
base location in colon biopsy specimens (Figure 7C).
Therefore, local colonic production of HD5 appeared to be a
signiﬁcant source of the colonic HD5 signal.
Assessment of Microgeographic
Distribution of Module Proteins
We used mucosal whole-mount immunohistochemistry
to attempt to visualize protein networks. Mucosal speci-
mens from surgical colonic resections of non-IBD and IBD
patients were evaluated with antibodies for the epithelial-
derived protein members of the yellow and pink modules.
In most specimens, only low expression was detected, as
expected for minimal constitutive expression levels of these
proteins (data not shown). However, some specimens
showed intense protein expression that occurred as an
intermittent mosaic of sites of small dimensions (diameter,
1–4 mm) (Figure 8A). This suggests that module proteins
are expressed intermittently at the mucosal surface in a
microgeographic pattern.
Discussion
General Features of Mucosal
Metaproteome in IBD
Concordant with our previous study of the mucosal–
luminal interface metaproteome, this independent data set
conﬁrmed that its two major properties are individual
variation, and a characteristic segmental feature dis-
tinguishing the proximal (cecum through descending) and
distal (rectum and sigmoid) colon. A recent independent
Table 3.Counts of Overlapped Peaks Between IBD and Normal Modules
IBD modules
M1 M2 M3 M4 M5 M6 M7 M8 M9
Non-IBD modules M1 28 2 1 0 0 0 1 0 3
M2 1 18 0 1 1 0 1 1 0
M3 0 0 0 12 0 0 1 2 2
M4 1 1 1 1 27 8 10 5 13
M5 5 9 4 8 3 42 12 41 75
M6 0 0 2 0 0 1 0 1 1
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Figure 4. Characterization of the yellow module. (A) The expression of the yellow module represented by its eigenproteins in
normal and IBD disease states. (B) Beanplots of representative protein levels detected in MALDI segregated by regions.
(C) Immunoblot detection of HNPs in mucosal lavage samples. (D) IHC detection of HNPs in human colonic biopsy specimens
(100). NM, normal.
576 Li et al Cellular and Molecular Gastroenterology and Hepatology Vol. 2, No. 5
study of the microbial-associated metaproteome has shown
distinct abundance patterns of microbial proteins among 6
regions of the gastrointestinal tract.14 The present study
adds two new observations regarding the mucosal–luminal
metaproteome. First, it presents evidence that disease state
also signiﬁcantly alters composition of this metaproteome.
Second, it uncovers a set of protein modules of the MLI
metaproteome, validated bioinformatically and conﬁrmed
by direct visualization using tissue-based cellular immuno-
histochemistry and immunoblot analysis.
Each protein module had a distinct segmental and disease
association. The expression of three modules (Yellow, Red,
and Blue) was associated selectively with both the colonic
regions and diseases. Two modules were overexpressed in
UC, and one module was overexpressed in both UC and CD.
Among the remaining modules, three show only disease
association, but no colonic segmental feature. The green
module was overexpressed in CD compared with both non-
IBD and UC, and both the black and brown modules were
underexpressed in UC and CD. There were also apparent
differences in the module structure between the IBD and
normal data sets. Four modules were highly conserved in
both data sets (cyan, green, brown, and black modules).
These modules may represent biologically resilient networks,
relatively unaffected in composition in non-IBD and IBD
states, even though the abundance of one such module
(green) was disease-associated (increased in CD). Other
modules were present in both data sets, but with different
hierarchical branches indicating module reorganization. For
instance, the yellow module of the normal data set consisted
of a single large module of 270 peaks, but was split into 4
smaller submodules (pink, yellow, blue, and red modules) in
the IBD data sets. Such reorganization of protein networks,
presumably reﬂecting the altered coordination of source cell
types at the mucosal surface, may provide fresh clues to
these physiologic and disease states of the mucosa.
Functional Features of the Index Module Proteins
Neutrophil inﬁltration of the mucosa is a common
occurrence in IBD, and thus provides a context for the
increased abundance of the neutrophil products HNP1–3,
and their associated yellow module, in the mucosal meta-
proteome of UC and CD. It is notable that their abundance
was observed in endoscopically quiescent sites, and was
increased in the distal colon of both normal and IBD
patients. Thus, the yellow module may reﬂect an underap-
preciated level of neutrophil engagement in the subclinical
physiologic inﬂammation of the distal colon.
HD5 is an a-defensin produced by ileal Paneth cells, and
its production is impaired in a subset of ileal Crohn’s disease
as a result of Paneth cell dysfunction associated with
Nucleotide-Binding Oligomerization Domain Containing 2
(NOD2) and Autophagy Related 16-Like 1(ATG16L1).39,40
UC and CD patients commonly acquire Paneth cell meta-
plasia, however, we also found HD5-positive cells in normal
colon biopsy specimens. This indicates that by the sensitive
detection of HD5 IHC, Paneth cell metaplasia also occurs in
clinically normal colonic mucosa, and may play an antimi-
crobial role in such sites of the distal intestine.
HBD1 and HBD2, predominantly produced by epithelial
cells, are minimally expressed in normal mucosa, but are
induced in active CD and UC.41,42 HBD2 is up-regulated by a
NOD2- or toll-like receptor-dependent nuclear factor-kB
pathway,43,44 but its intestinal expression may be indepen-
dent of NOD2 mutation status in CD patients.45 In this study,
both HBD1 and HBD2 were increased in CD patients
compared with normal and UC; this distinctive pattern may
reﬂect the antimicrobial peptide features of the colonic
mucosal surface compartment.
Transferrin and hepcidin are two important regulators of
iron homeostasis, and both are linked to innate immune
function and inﬂammation.38 Hepcidin regulates iron
Table 4.List of Identiﬁed Proteins/Peptides
Peak m/z Module Protein/peptide ID
2478.37 Cyan Ectonucleotide pyrophosphatase/
phosphodiesterase 7 (Homo sapiens)
3935.44 Cyan a-1 antitrypsin (H sapiens)
4135.65 Cyan a-1 antitrypsin (H sapiens)
2490.45 Green Immunoglobulin heavy-chain variable region
(Homo sapiens) or KIAA0297 (H sapiens)
2980.79 Green Peptidase M20 domain containing 1
(H sapiens)
3222.84 Green Pancreatic amylase a 2A (H sapiens)
3336.94 Green Dynamin-like protein
(Acaryochloris marina MBIC11017)
3992.28 Green b-defensin 1 (H sapiens)
4317.93 Green b-defensin 2 (H sapiens)
3583 Brown a-defensin5 (H sapiens)
2139.78 Pink Elastase 2A preproprotein (H sapiens)
2334.36 Pink ASAH2 protein (H sapiens)
3281.32 Pink Elastase 2A preproprotein (H sapiens)
3309.33 Pink Chymotrypsin-like elastase family
member 2A (H sapiens)
2313.27 Yellow Guanosine triphosphatase activating
Rap/RanGAP domain-like 1 isoform 1
(H sapiens)
2402.33 Yellow Tetratricopeptide TPR_2 repeat protein
(Flavobacteria bacterium)
3107.69 Yellow hCG2042445 (H sapiens)
3253.69 Yellow Tyrosine-protein kinase (Flavobacteria
bacterium BAL38)
3371.75 Yellow a-defensin 2 (H sapiens)
3442.69 Yellow a-defensin 1 (H sapiens)
3486.84 Yellow a-defensin 3 (H sapiens)
2052.13 Blue Haptoglobin (H sapiens) or anti–tumor
necrosis factor-a antibody heavy-chain
Fab fragment (H sapiens)
2159.68 Blue Chymotrypsin C preproprotein (H sapiens)
2197.11 Blue Procarboxypeptidase B (H sapiens)
2607.54 Blue Procarboxypeptidase B (H sapiens)
2721.59 Blue Transferrin (H sapiens)
2781.92 Blue Hepcidin (H sapiens)
11606.9 Blue Serum amyloid protein (H sapiens)
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homeostasis by binding to the sole iron exporter ferroportin
and promoting its internalization and degradation. Hepcidin
expression is abundant in hepatocytes. Our ﬁnding of pro-
hepcidin expression in the colonic epithelium supports this
novel local origin for hepcidin. Transferrin also is expressed
primarily by the liver, and is an abundant serum protein
that regulates iron homeostasis by binding tissue-derived
ferric ions and internalization by ubiquitous cellular trans-
ferrin receptors. We found abundant levels of transferrin in
the lamina propria, probably owing to such cellular uptake;
its vesicular intracellular localization is consistent with
this idea. Because both proteins reduce tissue ferric ions,
overexpression of both hepcidin and transferrin in UC
indicate a more active antimicrobial state. We show that
Figure 5. Characterization of the blue module. (A) The expression of the blue module represented by its eigenproteins in
normal and IBD disease states. (B) Beanplots of representative protein levels detected in MALDI segregated by regions: upper
panel, hepcidin; lower panel, transferrin. (C) Immunoblot detection of hepcidin and transferrin in mucosal lavage samples. (D)
IHC detection (100) of prohepcidin and transferrin in human colonic biopsy specimens (insets, 400). NM, normal control.
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colonic expression of hepcidin and transferrin are associ-
ated with IBD.
It is not surprising that the most abundantly identiﬁed
proteins in our mucosal surface samples were proteases and
protease inhibitors because these are major intestinal
epithelial products in support of alimentary enzymatic
digestion and metabolism. Curiously, the 6 proteins in this
category are associated with several distinct modules,
suggesting local factors that differentially affect their pro-
duction. Several host and microbial-derived proteases have
been associated with IBD,46,47 and increased concentrations
of proteases and proteolytic activities have been reported in
human fecal and colonic biopsy samples. The mechanism of
their differential control and their contribution to the IBD
disease state are open issues, but may relate to their
participation in the well-studied inﬂammatory tissue met-
alloprotease pathway.48
Mucosal Functional Networks
There is increasing evidence that the mucosal surface is
an integrated ecology formed by the interplay of host cell
types, environmental and dietary biomolecules, and
microbes.4,12–17,19,49 Based on the present metaproteomic
study, we hypothesize that the human mucosal surface is
Figure 6. (See previous page). Characterization of the green module. (A) The expression of the green module represented
by its eigenproteins in normal and IBD disease states. (B) Beanplots of representative protein levels detected in MALDI
segregated by regions (C) Immunoblot detection of proteins in mucosal lavage samples. left panel, HBD1;middle panel, HBD2;
right panel: PM20D1. (D) IHC detection (100) of HBD1, HBD2, and PM20D1 in human colonic biopsy specimens (insets,
400). NM, normal.
Figure 7. Expression of HD5 in colonic mucosal lavage and biopsy samples. (A) Immunoblot detection of HD5 in mucosal
lavage samples. (B) Quantitation of HD5 immunoblots. (C) IHC detection (100) of HD5 in human colonic biopsy specimens.
NM, normal.
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not homogeneous, but instead consists of local mucosal
functional networks (MFNs) (Figure 8B). Our bioinformatic
and immunohistochemistry data suggest that there may be a
few types of networks that are distributed in a mosaic of
microgeographic (millimeter-range) scale. We speculate that
these may form as host and microbial cells, and their
products may interact directly over a distance of microns to
millimeters, and in this physical range reach a metastable
composition and state of activity. Consistent with this idea,
recent work from Lee et al13 suggested that speciﬁc bacteria
may colonize unique areas of the gut, as shown by speciﬁc
localization of Bacteroides fragilis deep within crypt chan-
nels. Some MFNs also are likely to represent a habitat for
host responses such as inﬂammation, which may contribute
to preclinical or clinical disease states.
One limitation of the present study was that because of
the metaproteomics method used, our study mostly detec-
ted the human peptides of the mucosal metaproteome.
Accordingly, the relationship of the MFNs to microbial
interaction is uncertain. Recent advances in detection and
bioinformatics methods are enriching the identiﬁcation of
mucosal microbial proteins, and their use in assessing
microbial functional in the mucosal ecology.10–15 These
microbial ﬁndings, and the present human study, suggest
that integrated host-microbial metaproteomics will be a
promising approach to biochemically and functionally link
the local interaction of host, microbiota, and environmental
integration of the mucosal state.
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